AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9121823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain intensity (RIPP) over time
Number of subjects: 93
Study 9121823 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety and depression scores preoperatively
Number of subjects: 93
Study 9121823 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety and depression scores one year after surgery
Number of subjects: 93
Study 9121823 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of analgesics (opioids and NSAIDs)
Number of subjects: 93
Study 1848392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (equal milligram dosage)
Number of subjects: 47
Study 1848392 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (constant dosage)
Number of subjects: 47
Study 1848392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg tablet per day)
Number of subjects: 47
Study 1848392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg tablet per day)
Number of subjects: 47
Study 1848392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg tablet per day)
Number of subjects: 47
Study 1848392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 47
Study 6653136 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional capsules (600 mg disopyramide in 3 divided doses)
Number of subjects: 33
Study 6653136 — intervention group
Group type: COMPARATOR
Intervention: Conventional capsules (500 mg disopyramide daily for 11 days)
Number of subjects: 33
Study 6653136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablets (500 mg disopyramide daily for 11 days)
Number of subjects: 33
Study 6653136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablets (500 mg disopyramide daily for 30 days)
Number of subjects: 33
Study 6653136 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide treatment
Number of subjects: 33
Study 6653136 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide sustained-release tablets
Number of subjects: 33
Study 30785827 — intervention group
Group type: EXPERIMENTAL
Intervention: Defactinib
Number of subjects: 344
Study 30785827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 30785827 — intervention group
Group type: COMPARATOR
Intervention: Defactinib and Placebo
Number of subjects: 344
Study 30517586 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery relaxation therapy
Number of subjects: 24
Study 30517586 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 24
Study 26303936 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min)
Number of subjects: 23
Study 26303936 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 23
Study 24419112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus hypnosis (CBTH)
Number of subjects: 200
Study 24419112 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 200
Study 22442025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency IPC (2-s inflation/3-s deflation)
Number of subjects: 30
Study 22442025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency IPC (4-s inflation/16-s deflation)
Number of subjects: 30
Study 22442025 — intervention group
Group type: COMPARATOR
Intervention: IPC treatment
Number of subjects: 30
Study 20465893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy for one week
Number of subjects: 187
Study 20465893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy for two weeks
Number of subjects: 187
Study 20465893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy for four weeks
Number of subjects: 187
Study 17468821 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bupivacaine
Number of subjects: 80
Study 17468821 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ropivacaine
Number of subjects: 80
Study 17468821 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ropivacaine
Number of subjects: 80
Study 17468821 — intervention group
Group type: COMPARATOR
Intervention: Saline with epinephrine 1/200,000
Number of subjects: 80
Study 14699453 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine (2.5 mg/kg per day for 28 days)
Number of subjects: 80
Study 12048432 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 426
Study 12048432 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 426
Study 9524514 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage using Solcotrans Plus Orthopaedic devices
Number of subjects: 161
Study 8792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg) twice daily for 10 days
Number of subjects: 100
Study 8792486 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily for 10 days
Number of subjects: 100
Study 8792486 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg)
Number of subjects: 100
Study 8792486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2265168 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 20
Study 2265168 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine without epinephrine
Number of subjects: 20
Study 2265168 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine
Number of subjects: 20
Study 2265168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.5% bupivacaine with and without epinephrine)
Number of subjects: 20
Study 6895644 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 0
Study 6895644 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 6895644 — intervention group
Group type: EXPERIMENTAL
Intervention: maintenance sucralfate
Number of subjects: 0
Study 29290547 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2 (room without acoustic treatment with noise reproduction)
Number of subjects: 27
Study 29290547 — intervention group
Group type: COMPARATOR
Intervention: Condition 1 (room without acoustic treatment and without noise reproduction)
Number of subjects: 27
Study 29020983 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 (40 mg) administered orally twice daily for 24 weeks
Number of subjects: 90
Study 29020983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26185325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1‐mmol/kg gadobenate
Number of subjects: 177
Study 26185325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05‐mmol/kg gadobenate
Number of subjects: 177
Study 26185325 — intervention group
Group type: COMPARATOR
Intervention: 0.1‐mmol/kg gadoterate
Number of subjects: 177
Study 25252423 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 169
Study 25252423 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 169
Study 22348338 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid therapy
Number of subjects: 0
Study 22348338 — intervention group
Group type: COMPARATOR
Intervention: Control gene hARP-P0
Number of subjects: 0
Study 20651683 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-diabetic PPARγ 3 ligands (rosiglitazone, MRL24)
Number of subjects: 0
Study 20651683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 16968726 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin-alpha (SC-EPO; EPREX; 1000 U twice weekly)
Number of subjects: 197
Study 16968726 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epoetin-alpha (SC-EPO; 2000 U three times weekly)
Number of subjects: 197
Study 16287442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL lidocaine‐prilocaine cream
Number of subjects: 200
Study 16287442 — intervention group
Group type: COMPARATOR
Intervention: 5 mL placebo
Number of subjects: 200
Study 11888953 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg, once daily for 4 weeks
Number of subjects: 29
Study 11888953 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet, once daily for 4 weeks
Number of subjects: 29
Study 10220627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lidocaine
Number of subjects: 43704
Study 10220627 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine
Number of subjects: 43704
Study 7825527 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g fine coffee grounds per day for 3 weeks
Number of subjects: 15
Study 7825527 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine coffee grounds for 10 days
Number of subjects: 15
Study 7825527 — intervention group
Group type: COMPARATOR
Intervention: Coarse coffee grounds for 10 days
Number of subjects: 15
Study 2083170 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (Kwai) for 12 weeks
Number of subjects: 47
Study 2083170 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 47
Study 670607 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 54
Study 31988276 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor-derived DNA (ctDNA) analysis through ultrasensitive targeted sequencing of matched cfDNA and white blood cells.
Number of subjects: 0
Study 31988276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment and surgical resection (multimodal treatment).
Number of subjects: 0
Study 31236679 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated acute appendicitis (surgical treatment arm of the APPAC trial)
Number of subjects: 0
Study 28464867 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change communication (BCC) on maternal nutrition during pregnancy, exclusive breastfeeding, and complementary feeding, along with prenatal nutritional supplement (PNS) and complementary food supplement (CFS)
Number of subjects: 1500
Study 28464867 — intervention group
Group type: EXPERIMENTAL
Intervention: BCC with PNS
Number of subjects: 1500
Study 28464867 — intervention group
Group type: EXPERIMENTAL
Intervention: BCC with CFS
Number of subjects: 1500
Study 28464867 — intervention group
Group type: EXPERIMENTAL
Intervention: BCC alone
Number of subjects: 1500
Study 28464867 — intervention group
Group type: COMPARATOR
Intervention: Routine health and nutrition services (comparison arm)
Number of subjects: 1500
Study 25929208 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic version of SRS‐22r questionnaire (reliability testing group)
Number of subjects: 81
Study 25929208 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic version of SRS‐22r questionnaire (validity testing group)
Number of subjects: 81
Study 23218022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus low-dose risperidone
Number of subjects: 115
Study 23218022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus placebo
Number of subjects: 115
Study 23218022 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy plus placebo
Number of subjects: 115
Study 21690083 — intervention group
Group type: EXPERIMENTAL
Intervention: DIR/Floortime™ intervention (average of 15.2 hours/week for three months)
Number of subjects: 0
Study 19453962 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 12
Study 16713737 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 34
Study 16713737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 14747294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 41
Study 11697643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 0
Study 11697643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies involving vaccines
Number of subjects: 0
Study 9549738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 2 mg.kg‐1
Number of subjects: 40
Study 9549738 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% 2 mg.kg‐1
Number of subjects: 40
Study 9115058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 24
Study 9115058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 4 mg
Number of subjects: 24
Study 9115058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 8 mg
Number of subjects: 24
Study 9115058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 10 mg
Number of subjects: 24
Study 9115058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2716477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day) with naloxone (1.6 mg/h for 4 h)
Number of subjects: 9
Study 2716477 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (5 mg/day) with saline
Number of subjects: 9
Study 1017879 — intervention group
Group type: EXPERIMENTAL
Intervention: +Pat. (antibiotic prophylaxis with penicillins or cephalosporins)
Number of subjects: 133
Study 1017879 — intervention group
Group type: COMPARATOR
Intervention: ‐Pat. (no antibiotic treatment)
Number of subjects: 133
Study 1017879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubated patients
Number of subjects: 133
Study 31326458 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus fixed-dose combination glimepiride 1 mg and metformin 500 mg twice daily (G/M group)
Number of subjects: 97
Study 31326458 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine plus glimepiride 4 mg once daily (G group)
Number of subjects: 97
Study 26975399 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% (four times daily for 6 weeks post-surgery)
Number of subjects: 108
Study 26975399 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative care with steroid drop
Number of subjects: 108
Study 26975399 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1%
Number of subjects: 108
Study 26088896 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (DB-PER)
Number of subjects: 0
Study 26088896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DB-PBO)
Number of subjects: 0
Study 26088896 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (DB-PER 12 mg)
Number of subjects: 0
Study 23510102 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing counseling with 21‐mg nicotine patch
Number of subjects: 430
Study 23510102 — intervention group
Group type: COMPARATOR
Intervention: Standard care (one session of brief advice to quit smoking) with 21‐mg nicotine patch
Number of subjects: 430
Study 23510102 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing counseling
Number of subjects: 430
Study 23510102 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 430
Study 21864166 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily for 1 year)
Number of subjects: 1142
Study 21864166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1142
Study 19825960 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA cytometry testing
Number of subjects: 23993
Study 19825960 — intervention group
Group type: COMPARATOR
Intervention: Cytologic testing
Number of subjects: 23993
Study 19825960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests used together
Number of subjects: 23993
Study 19825960 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events after treatment
Number of subjects: 23993
Study 16415935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofric catheter
Number of subjects: 196
Study 16415935 — intervention group
Group type: COMPARATOR
Intervention: SpeediCath catheter
Number of subjects: 196
Study 15288215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 100
Study 15288215 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 100
Study 15288215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 11737375 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 823
Study 11737375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 823
Study 11737375 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir hard gel
Number of subjects: 823
Study 11737375 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 823
Study 9161875 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at 0.1 IU/kg/day
Number of subjects: 230
Study 9161875 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at 0.2 IU/kg/day
Number of subjects: 230
Study 9161875 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at 0.3 IU/kg/day
Number of subjects: 230
Study 9161875 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study 8260285 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely controlled mechanical pump for contrast injection
Number of subjects: 319
Study 8260285 — intervention group
Group type: COMPARATOR
Intervention: Hand injection of contrast
Number of subjects: 319
Study 3288942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis-induced analgesia
Number of subjects: 28
Study 3288942 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-induced analgesia
Number of subjects: 28
Study 31350080 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS and training
Number of subjects: 38
Study 31350080 — intervention group
Group type: COMPARATOR
Intervention: sham a‐tDCS and training
Number of subjects: 38
Study 31350080 — intervention group
Group type: COMPARATOR
Intervention: training only
Number of subjects: 38
Study 28302411 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 3484
Study 28302411 — intervention group
Group type: COMPARATOR
Intervention: IIV3-YAM
Number of subjects: 3484
Study 28302411 — intervention group
Group type: COMPARATOR
Intervention: IIV3-VIC
Number of subjects: 3484
Study 26692555 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 200
Study 23771530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-inducing protocol consisting of intermittent isometric contractions of the leg extensors or flexors using a 0.6 duty cycle (6 s contraction, 4 s relaxation) at 60 % of MVC until volitional fatigue
Number of subjects: 36
Study 23771530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-inducing protocol
Number of subjects: 36
Study 21794012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellooligosaccharide (CE) feeding group (n = 16)
Number of subjects: 52
Study 21794012 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (SB) feeding group (n = 18)
Number of subjects: 52
Study 21794012 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 52
Study 18653328 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400mg b.i.d. for 7 days)
Number of subjects: 23
Study 18653328 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 23
Study 17276955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade cardioplegia (Group 1)
Number of subjects: 20
Study 17276955 — intervention group
Group type: COMPARATOR
Intervention: Intermittent antegrade cardioplegia supplemented by antegrade perfusion of vein grafts (Group 2)
Number of subjects: 20
Study 12942029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of spironolactone plus standard therapy
Number of subjects: 51
Study 12942029 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only (Control group)
Number of subjects: 51
Study 10780135 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of husbands' alliance assessed at Session 1
Number of subjects: 70
Study 10780135 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of wives' alliance assessed at Session 1
Number of subjects: 70
Study 10780135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alliance
Number of subjects: 70
Study 8761840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training based on 60% to 80% of peak oxygen intake (VO2max) and/or ventilatory threshold (VT) with perceived exertion of 12 to 14 on the Borg scale
Number of subjects: 20
Study 1342896 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily for 7 days
Number of subjects: 142
Study 1342896 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily for 7 days
Number of subjects: 142
Study 3908127 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group A with heavy osmotic hydration
Number of subjects: 20
Study 3908127 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP (cis‐diammine‐dichloroplatinum II) 50 mg/m2 in Group B over 3 consecutive days
Number of subjects: 20
Study 30747780 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery intervention group
Number of subjects: 60
Study 30747780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 28919191 — intervention group
Group type: EXPERIMENTAL
Intervention: RESTORE program (9‐12 individual yoga sessions)
Number of subjects: 68
Study 28919191 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 68
Study 26385228 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (100 mg daily for 8 weeks)
Number of subjects: 60
Study 26385228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25297013 — intervention group
Group type: EXPERIMENTAL
Intervention: ALD403 1000 mg
Number of subjects: 163
Study 25297013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 23427759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anesthesia (group A)
Number of subjects: 150
Study 23427759 — intervention group
Group type: COMPARATOR
Intervention: Digital-guided anesthesia (group B)
Number of subjects: 150
Study 19074540 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobic exposure in spider phobic subjects
Number of subjects: 32
Study 19074540 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32